Article

Correlation between the Clinical Treatment Score Post 5 years (CTS5) and the Oncotype DX 21-gene recurrence score (ODX-RS); can we accurately predict patients who require extended adjuvant hormonal manipulation.

2022-11-18

Abstract excerpt

<h4>Background: </h4> . While hormone receptor-positive (HR+), HER 2-negative (HER2-), node-negative breast cancer is associated with an excellent overall prognosis, it possesses a unique penchant for late recurrence. Estimating breast cancer recurrence has traditionally relied on clinicopathologic markers, such as those underpinning the Clinical Treatment Score Post 5 years (CTS5) but there is an increasing depen...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1d835e42-405e-5ca0-9205-40a3fa624556
DOI: 10.21203/rs.3.rs-2274943/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Correlation between the Clinical Treatment Score Post 5 years (CTS5) and the Oncotype DX 21-gene recurrence score (ODX-RS); can we accurately predict patients who require extended adjuvant hormonal manipulation.DOI 10.21203/rs.3.rs-2274943/v1Read

Utilization and Outcomes of the 21-Gene Recurrence Score in pN2 Breast Cancer PatientsSemantic proximity Read

Impact of Different Modules of 21-Gene Assay in Early Breast Cancer PatientsSemantic proximity Read

21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010-2013.Semantic proximity Read

Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations.Semantic proximity Read

Application of a 21-Gene Recurrence Score in a Swiss Single Center Breast Cancer Population. A Comparative Analysis of Treatment Administration before and after TAILORxSemantic proximity Read

Clarification attempt of the mechanism of late recurrence by micro- and macro-analyses in estrogen receptor-positive breast cancerSemantic proximity Read

A 95-gene Signature Stratifies Recurrence Risk of Invasive Disease in ER-positive, HER2-negative, Node-negative Breast Cancer With Intermediate 21-gene Signature Recurrence ScoresSemantic proximity Read

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast CancerSemantic proximity Read

Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen.Semantic proximity Read

A nomogram to predict the high-risk RS in HR+/HER2-breast cancer patients older than 50 years of ageSemantic proximity Read

Utility of the 21-Gene Recurrence Score in Node-Positive Breast Cancer.Semantic proximity Read

Favorable Locoregional Control in Clinically Node- Negative Hormone-receptor Positive Breast Cancer With Low 21-gene Recurrence Scores: a Single Institutional Study With 10-year Follow-upSemantic proximity Read